- Home
- EVAX vs PMD Comparison
EVAX vs PMD Comparison
Compare EVAX & PMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVAX
- PMD
- Stock Information
- Founded
- EVAX 2008
- PMD 1986
- Country
- EVAX Denmark
- PMD United States
- Employees
- EVAX N/A
- PMD N/A
- Industry
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- PMD Medical Specialities
- Sector
- EVAX Health Care
- PMD Health Care
- Exchange
- EVAX Nasdaq
- PMD Nasdaq
- Market Cap
- EVAX 14.3M
- PMD 13.7M
- IPO Year
- EVAX 2021
- PMD N/A
- Fundamental
- Price
- EVAX $1.37
- PMD $2.34
- Analyst Decision
- EVAX Strong Buy
- PMD
- Analyst Count
- EVAX 2
- PMD 0
- Target Price
- EVAX $11.00
- PMD N/A
- AVG Volume (30 Days)
- EVAX 40.9K
- PMD 25.1K
- Earning Date
- EVAX 10-31-2024
- PMD 11-12-2024
- Dividend Yield
- EVAX N/A
- PMD N/A
- EPS Growth
- EVAX N/A
- PMD N/A
- EPS
- EVAX N/A
- PMD N/A
- Revenue
- EVAX $3,295,000.00
- PMD $20,258,000.00
- Revenue This Year
- EVAX $4,845.21
- PMD N/A
- Revenue Next Year
- EVAX $30.30
- PMD N/A
- P/E Ratio
- EVAX N/A
- PMD N/A
- Revenue Growth
- EVAX N/A
- PMD N/A
- 52 Week Low
- EVAX $1.28
- PMD $1.63
- 52 Week High
- EVAX $13.61
- PMD $3.93
- Technical
- Relative Strength Index (RSI)
- EVAX 22.79
- PMD 53.66
- Support Level
- EVAX $1.28
- PMD $2.31
- Resistance Level
- EVAX $1.80
- PMD $2.35
- Average True Range (ATR)
- EVAX 0.27
- PMD 0.02
- MACD
- EVAX -0.10
- PMD -0.00
- Stochastic Oscillator
- EVAX 6.08
- PMD 50.00
About EVAX Evaxion Biotech A/S
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.
About PMD Psychemedics Corporation
Psychemedics Corp is engaged in providing testing services for the detection of drugs of abuse through the analysis of hair samples. The company operates through a single segment of drug testing services which include training for the collection of samples and storage of positive samples for its customers for an agreed-upon fee per unit testing of samples. The testing methods of the company utilize a patented technology that digests the hair and releases drugs trapped in the hair without destroying the drugs. They provide testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples. Geographically it generates the majority of its revenue from the United States.